Khushbu Chandarana
Endocrinology, Diabetes & Metabolism · Cary, NCNPI 1609084151
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $498 and has fallen 68.1% since, to $159 in 2025.
Across 113 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$390
- Abbott$214
- Lilly USA, LLC$182
- Sanofi-aventis U.S. LLC$80
- Medtronic$77
- Insulet Corporation$73
- plus $871 from 30 others
Across 1 payment — averaging $50,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$51K
What the payments were for
- Food & beverage$1,79395%
- Education$945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $390 |
| Abbott | 11 | $214 |
| Lilly USA, LLC | 10 | $182 |
| Sanofi-aventis U.S. LLC | 6 | $80 |
| Medtronic(2 entities) | 5 | $77 |
| Insulet Corporation | 4 | $73 |
| Johnson & Johnson(2 entities) | 5 | $72 |
| Neurocrine Biosciences, Inc. | 3 | $69 |
| Dexcom, Inc. | 3 | $68 |
| Amgen(2 entities) | 4 | $57 |
| Daiichi Sankyo Inc. | 3 | $52 |
| IBSA Pharma Inc. | 3 | $45 |
| Shire North American Group Inc | 3 | $45 |
| Senseonics, Incorporated | 2 | $43 |
| Novartis | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| EMD Serono, Inc. | 2 | $29 |
| Radius Health, Inc. | 2 | $27 |
| GSK | 2 | $26 |
| Antares Pharma, Inc. | 2 | $23 |
| Bayer | 1 | $22 |
| Sanofi | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Pharmaessentia USA Corporation | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Cequr Corporation | 1 | $9 |
| Clarus Therapeutics Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
How this compares
$1,886 in reported general payments places this provider in the 55th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 14 | $55,831 |
| OzempicSemaglutide | 13 | $19,493 |
| SynthroidLevothyroxine Sodium | 13 | $771 |
| Levothyroxine Sodium | 14 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $182 | $55,83114 claims |
| Novo NordiskOzempic | $390 | $19,49313 claims |
| AbbVieSynthroid | $18 | $77113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Cary
- Sung-Eun YooCary$21K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.